Related Experiment Video
Updated: Mar 19, 2026
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Positive inotropes in heart failure: a review article
1Department of Heart failure and Transplantation, Rajaee Cardiovascular, Medical and Research Center, Tehran University of Medical Science, Tehran, Iran.
Insights
Inotropes can improve heart function in systolic heart failure but require careful, short-term use. Recent guidelines help clinicians optimize inotrope therapy for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Increasing myocardial contractility is a key strategy for managing systolic heart failure.
- Inotropes offer hemodynamic benefits like higher cardiac output and improved organ perfusion.
- Despite safety concerns, inotropes remain a vital treatment in heart failure management.
Purpose of the Study:
- To review clinical trials of agents that increase cardiac contractility in heart failure patients.
- To focus on recent guidelines for optimizing inotrope use in heart failure.
Main Methods:
- Review of clinical trials involving inotropic agents for systolic heart failure.
- Analysis of current evidence-based guidelines for inotrope application.
Main Results:
- Inotropes provide hemodynamic advantages in systolic heart failure.
- Clinical trials have raised safety concerns regarding inotrope use.
- Guidelines emphasize short duration, low dose, and early discontinuation of inotropes.
Conclusions:
- Inotropic therapy requires judicious application, balancing benefits against risks.
- Adherence to guidelines is crucial for safe and effective inotrope use.
- Optimizing inotropes can improve the management of heart failure patients.
Abstract:
Increasing myocardial contractility has long been considered a big help for patients with systolic heart failure, conferring an augmented haemodynamic profile in terms of higher cardiac output, lower cardiac filling pressure and better organ perfusion. Though concerns have been raised over the safety issues regarding the clinical trials of different inotropes in hearts with systolic dysfunction, they still stand as a main therapeutic strategy in many centres dealing with such patients. They must be used as short in duration, low in dose and stopped as early as possible. Evidence-based guidelines have provided clinicians with valuable data for better applying inotropes in heart failure patients. In this paper, the authors address clinical trials with different agents used for increasing cardiac contractility in heart failure patients. Furthermore, the authors focus on recent guidelines on making the most out of inotropes in heart failure patients.
